Global Diabetic Nephropathy Market 2014-2018


Naperville, IL -- (SBWIRE) -- 03/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Diabetic Nephropathy Market 2014-2018 market report to its offering
About Diabetic Nephropathy
Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.
Analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.
Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
Merck & Co. Inc.
Mitsubishi Tanabe Pharma Corp.
Novartis AG
Sanofi S.A.
Other Prominent Vendors

AbbVie Inc.
Ampio Pharmaceuticals Inc.
Astellas Pharma Inc.
Bayer AG
ChemoCentryx Inc.
Eli Lilly and Co.
GenKyoTex S.A.
Glycadia Pharmaceuticals Inc.
Mesoblast Ltd.
NephroGenex Inc.
Novo Nordisk A/S
OncoImmune Inc.
Pfizer Inc.
PhytoHealth Corp.
Questcor Pharmaceuticals Inc.
Reata Pharmaceuticals Inc.
Key Market Driver
Increase in Prevalence of Diabetes.
For a full, detailed list, view our report.
Key Market Challenge
Increasing Number of Patent Expirations.
For a full, detailed list, view our report.
Key Market Trend
Increase in Awareness of Diabetic Nephropathy Drugs.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
More Information about Diabetic Nephropathy

Companies Mentioned

Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Sanofi S.A., AbbVie Inc., Ampio Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, ChemoCentryx Inc.. Eli Lilly and Co., GenKyoTex S.A., Glycadia Pharmaceuticals Inc., IMMD Inc., Mesoblast Ltd., NephroGenex Inc., Novo Nordisk A/S, NOXXON Pharma AG, OncoImmune Inc., Pfizer Inc., PhytoHealth Corp., Questcor Pharmaceuticals Inc., Reata Pharmaceuticals Inc.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604